Pembrolizumab can be safely combined with either sequential or concomitant stereotactic body radiotherapy (SBRT) for treating metastatic urothelial carcinoma. New data from a randomized phase I trial reported no dose-limiting toxic effects or grade 4 or 5 adverse events for either combination; one grade 3 adverse event occurred in the concomitant SBRT arm. Overall response rates were 0% and 44.4% in the sequential arm and the concomitant arm, respectively, but the trial was not powered to compare efficacy between treatment arms. Overall, pembrolizumab plus SBRT was well tolerated for treating metastatic urothelial carcinoma.
References
Original article
Sundahl, N. et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur. Urol. https://doi.org/10.1016/j.eururo.2019.01.009 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stone, L. Treatment timing well tolerated in bladder cancer. Nat Rev Urol 16, 206 (2019). https://doi.org/10.1038/s41585-019-0162-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0162-x
